Emerging treatments
Your Organisational Guidance
ebpracticenet urges you to prioritise the following organisational guidance:
Kleincellige en niet-kleincellige longkanker: diagnose, behandeling en opvolgingPublished by: KCELast published: 2013Cancer du poumon à petites cellules et non à petites cellules : diagnostic, traitement et suiviPublished by: KCELast published: 2013Adebrelimab
In patients with extensive-stage small-cell lung cancer (ES-SCLC), adebrelimab plus etoposide and carboplatin significantly improved overall survival compared with placebo plus etoposide and carboplatin.[78]
Toripalimab
The programmed cell death 1 (PD-1) inhibitor, toripalimab, has been granted orphan drug designation for SCLC in the US. Compared with placebo plus platinum-based chemotherapy (cisplatin or carboplatin plus etoposide), toripalimab plus chemotherapy significantly improved progression-free and overall survival in patients with ES-SCLC.[79]
Serplulimab
The PD-1 inhibitor serplulimab has been granted orphan drug designation for SCLC in the US. In the ASTRUM-005 trial, first-line treatment with serplulimab plus chemotherapy in patients with extensive-stage SCLC resulted in improved overall survival compared with chemotherapy alone.[80]
Stereotactic radiosurgery
Stereotactic radiosurgery has superseded whole brain radiotherapy (WBRT) as the first-line treatment for intracranial metastatic disease in most solid cancers. However, WBRT remains the first-line treatment for intracranial metastatic disease in patients with SCLC. One meta-analysis reported that survival outcomes are similar following treatment with SRS or with WBRT in patients with SCLC and intracranial metastatic disease.[81]
Use of this content is subject to our disclaimer